Menarini licenses European rights to investigational GLP-1 drug bofanglutide

Gan & Lee Pharmaceuticals and Menarini announced an exclusive European licensing agreement on September 3 for bofanglutide, an investigational GLP-1 receptor agonist being developed for adults with obesity or overweight. The partnership gives the candidate a regional regulatory and commercial pathway as developers explore less frequent administration of peptide medicines for metabolic disease.

Menarini will handle regulatory submissions and commercialization across 39 countries, including all 27 European Union members and the United Kingdom. The announced terms include a €62 million upfront payment, up to €664 million in milestones and double-digit royalties. The €726 million potential total excludes royalties and depends largely on future milestones.

Bofanglutide, also called GZR18, remains investigational. The agreement does not establish European marketing authorization or patient availability.

What the published obesity trial shows

A randomized, double-blind, placebo-controlled phase 2b trial published in Signal Transduction and Targeted Therapy on February 27 provides evidence behind the development program. It enrolled 340 Chinese adults with obesity, or overweight accompanied by a weight-related condition. Their average age was 33.1 years.

Participants received one of several bofanglutide regimens or placebo. The primary endpoint was percentage change in body weight after 30 weeks. Across active-treatment groups, average weight reductions ranged from 9.75% to 16.69%, compared with 1.15% for placebo. These figures span different regimens; they are not a single expected result for the proposed commercial product.

Gastrointestinal adverse events occurred in 83.9% of bofanglutide recipients and 33.3% of placebo recipients, mostly at mild or moderate severity. Overall, 286 participants completed the trial.

The study supports biological activity and further testing. Its duration and exclusively Chinese population limit conclusions about sustained treatment and broader populations. The relatively young participants also provide limited guidance about frail older adults, for whom tolerability and preservation of function matter alongside weight reduction.

Diabetes evidence answers a different question

A separate published phase 2b trial compared bofanglutide with semaglutide in 272 adults with type 2 diabetes at 37 Chinese sites. This randomized study was open-label, meaning participants and investigators knew the assigned treatment. Its primary endpoint was change in HbA1c, a measure of longer-term blood glucose, at 24 weeks.

HbA1c reductions across bofanglutide groups ranged from 1.87 to 2.32 percentage points, compared with 1.60 percentage points in the semaglutide group. Gastrointestinal events occurred in approximately 82% to 87% of bofanglutide recipients and 52% of semaglutide recipients.

Those findings concern specific diabetes regimens and a glucose endpoint. They cannot establish superiority over semaglutide for obesity treatment. The authors identified the open-label design, short follow-up and exclusively Chinese enrollment as limitations. Gan & Lee funded the study.

What remains to be demonstrated

The companies say Gan & Lee intends to initiate a global phase 3 program supporting registration in Europe and other markets. That planned program is a future development step.

For readers following healthspan research, the distinction between metabolic measurements and clinical outcomes is central. The published studies described here evaluated weight or glucose control over months. They do not establish that bofanglutide prevents cardiovascular events, preserves independence or extends life.

An every-two-week schedule could offer practical convenience, but fewer administrations alone do not demonstrate better adherence or a superior balance of benefits and harms. Those questions require direct evidence as the program advances.